Statistical controversies in clinical research: assessing pathologic complete response as a trial-level surrogate end point for early-stage breast cancer

被引:39
作者
Korn, E. L. [1 ]
Sachs, M. C. [1 ]
McShane, L. M. [1 ]
机构
[1] NCI, Biometr Res Branch, Div Canc Treatment & Diag, Bethesda, MD 20892 USA
关键词
breast cancer; pathologic complete response; surrogate end point; trial-level surrogate end point; randomized clinical trial; screening trials; NEOADJUVANT THERAPY; OPEN-LABEL; MULTICENTER; TRASTUZUMAB; LAPATINIB; NEOALTTO;
D O I
10.1093/annonc/mdv507
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A trial-level surrogate end point for a randomized clinical trial may allow assessment of the relative benefits of the treatment to be performed at an earlier time point and potentially with a smaller sample size. However, determining whether an end point is a reliable trial-level surrogate based on results of previous trials is not straightforward. The question of trial-level surrogacy is easily confused with the question of individual-level surrogacy, and this confusion can lead to controversy. A recent example concerns the evaluation of pathologic complete response (pCR) as a surrogate for event-free survival (EFS) and overall survival (OS) in early-stage breast cancer. The differences between individual-level surrogacy (i.e. for patients receiving a specific treatment, the surrogate end point predicts the definitive end point) and trial-level surrogacy (the results of the trial for the surrogate end point predict the results of the trial for the definitive end point) are discussed. Trial-level data used in two previous meta-analyses evaluating pCR as a trial-level surrogate for EFS and OS were re-analyzed using methods that appropriately account for the variability in pCR rates as well as the variability in the hazard ratios for EFS and OS. There is no evidence that pCR is a trial-level surrogate for EFS or OS, nor is there evidence that pCR could be used reliably to screen out nonpromising agents from further drug development. At present, neoadjuvant RCTs should continue to follow patients to observe EFS and OS to assess clinical benefit, and they should be designed with sufficient sample size to reliably assess EFS. However, one cannot rule out the possibility that future meta-analyses involving more trials and in which the patient population or class of treatments is restricted could suggest the validity of pCR as a trial-level surrogate for EFS or OS in some focused settings.
引用
收藏
页码:10 / 15
页数:6
相关论文
共 50 条
[41]   The effect of music listening intervention applied during radiation therapy on the anxiety and comfort level in women with early-stage breast cancer: A randomized controlled trial [J].
Karadag, Ezgi ;
Ugur, Ozlem ;
Cetinayak, Oguz .
EUROPEAN JOURNAL OF INTEGRATIVE MEDICINE, 2019, 27 :39-44
[42]   Pathologic Complete Response Rates After Neoadjuvant Pertuzumab and Trastuzumab with Chemotherapy in Early Stage HER2-Positive Breast Cancer-Increasing Rates of Breast Conserving Surgery: A Real-World Experience [J].
Boer, Katalin ;
Kahan, Zsuzsanna ;
Landherr, Laszlo ;
Csoszi, Tibor ;
Mahr, Karoly ;
Ruzsa, Agnes ;
Horvath, Zsolt ;
Budai, Barna ;
Rubovszky, Gabor .
PATHOLOGY & ONCOLOGY RESEARCH, 2021, 27
[43]   Tumor Biology Correlates With Rates of Breast-Conserving Surgery and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer Findings From the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial [J].
Boughey, Judy C. ;
McCall, Linda M. ;
Ballman, Karla V. ;
Mittendorf, Elizabeth A. ;
Ahrendt, Gretchen M. ;
Wilke, Lee G. ;
Taback, Bret ;
Leitch, A. Marilyn ;
Flippo-Morton, Teresa ;
Hunt, Kelly K. .
ANNALS OF SURGERY, 2014, 260 (04) :608-616
[44]   Pathologic Complete Response Achieved in Early- Stage HER2-Positive Breast Cancer After Neoadjuvant Therapy With Trastuzumab and Chemotherapy vs. Trastuzumab, Chemotherapy, and Pertuzumab: A Systematic Review and Meta- Analysis of Clinical Trials [J].
Fazal, Faizan ;
Bashir, Muhammad Nauman ;
Adil, Maham Leeza ;
Tanveer, Usama ;
Ahmed, Mansoor ;
Chaudhry, Taha Zahid ;
Ijaz, Ali Ahmad ;
Haider, Muhammad .
CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (05)
[45]   Quantitative Changes in Intratumoral Habitats on MRI Correlate With Pathologic Response in Early-stage ER/PR+HER2-Breast Cancer Treated With Preoperative Stereotactic Ablative Body Radiotherapy [J].
Weinfurtner, R. Jared ;
Abdalah, Mahmoud ;
Stringfield, Olya ;
Ataya, Dana ;
Williams, Angela ;
Mooney, Blaise ;
Rosa, Marilin ;
Lee, Marie C. ;
Khakpour, Nazanin ;
Laronga, Christine ;
Czerniecki, Brian ;
Diaz, Roberto ;
Ahmed, Kamran ;
Washington, Iman ;
Latifi, Kujtim ;
Niell, Bethany L. ;
Montejo, Michael ;
Raghunand, Natarajan .
JOURNAL OF BREAST IMAGING, 2022, 4 (03) :273-284
[46]   Effect of Acupuncture vs Sham Acupuncture or Waitlist Control on Joint Pain Related to Aromatase Inhibitors Among Women With Early-Stage Breast Cancer A Randomized Clinical Trial [J].
Hershman, Dawn L. ;
Unger, Joseph M. ;
Greenlee, Heather ;
Capodice, Jillian L. ;
Lew, Danika L. ;
Darke, Amy K. ;
Kengla, Alice T. ;
Melnik, Marianne K. ;
Jorgensen, CarlaW. ;
Kreisle, William H. ;
Minasian, Lori M. ;
Fisch, Michael J. ;
Henry, N. Lynn ;
Crew, Katherine D. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2018, 320 (02) :167-176
[47]   Clinical efficacy and biomarker analysis of neoadjuvant camrelizumab plus chemotherapy for early-stage triple-negative breast cancer: a experimental single-arm phase II clinical trial pilot study [J].
Zheng, Chunhui ;
Liu, Yanbing ;
Wang, Xue'er ;
Bi, Zhao ;
Qiu, Pengfei ;
Qiao, Guangdong ;
Bi, Xiang ;
Shi, Zhiqiang ;
Zhang, Zhaopeng ;
Chen, Peng ;
Sun, Xiao ;
Wang, Chunjian ;
Zhu, Shiguang ;
Meng, Xiangjing ;
Song, Yunjie ;
Qi, Yingxue ;
Li, Lu ;
Luo, Ningning ;
Wang, Yongsheng .
INTERNATIONAL JOURNAL OF SURGERY, 2024, 110 (03) :1527-1536
[48]   Efficacy, cardiotoxicity and factors affecting pathologic complete response of neoadjuvant chemotherapy with anthracycline-containing verses anthracycline-free regimens plus dual HER2 blockade for HER2-positive early-stage breast cancer: a retrospective study [J].
Lu, Hang ;
Yan, Han ;
Liao, Shichong ;
Deng, Jingwen ;
Zhang, Jiucheng ;
Yao, Feng ;
Zheng, Hongmei ;
Sun, Shengrong ;
Zhang, Yimin .
TRANSLATIONAL CANCER RESEARCH, 2023, 12 (06) :1490-1502
[49]   Sentinel Lymph Node Biopsy Versus Axillary Dissection in Node-Negative Early-Stage Breast Cancer: 15-Year Follow-Up Update of a Randomized Clinical Trial [J].
Giuseppe Canavese ;
Paolo Bruzzi ;
Alessandra Catturich ;
Daniela Tomei ;
Franca Carli ;
Elsa Garrone ;
Stefano Spinaci ;
Federico Lacopo ;
Corrado Tinterri ;
Beatrice Dozin .
Annals of Surgical Oncology, 2016, 23 :2494-2500
[50]   Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil-epirubicin-cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy [J].
Ohno, S. ;
Chow, L. W. C. ;
Sato, N. ;
Masuda, N. ;
Sasano, H. ;
Takahashi, F. ;
Bando, H. ;
Iwata, H. ;
Morimoto, T. ;
Kamigaki, S. ;
Nakayama, T. ;
Nakamura, S. ;
Kuroi, K. ;
Aogi, K. ;
Kashiwaba, M. ;
Yamashita, H. ;
Hisamatsu, K. ;
Ito, Y. ;
Yamamoto, Y. ;
Ueno, T. ;
Fakhrejahani, E. ;
Yoshida, N. ;
Toi, M. .
BREAST CANCER RESEARCH AND TREATMENT, 2013, 142 (01) :69-80